Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled...

Area of Science:

• Pediatric Urology
• Pharmacology
• Clinical Trials

Background:

• Overactive bladder (OAB) significantly impacts children's quality of life.
• Current OAB treatments in pediatrics have limitations and potential side effects.

Purpose of the Study:

• To compare the efficacy and safety of mirabegron versus solifenacin in treating newly diagnosed pediatric OAB.
• To evaluate treatment outcomes using voiding diaries and symptom relief assessments.

Main Methods:

• Prospective randomized controlled study involving 190 pediatric patients (5-14 years) with newly diagnosed OAB.
• Patients were randomized into three groups: mirabegron, solifenacin, or placebo.
• Efficacy and safety were assessed over a 3-month period using voiding diaries and adverse event recording.

Main Results:

• Both mirabegron and solifenacin demonstrated significant improvement in OAB symptoms compared to placebo.
• Success rates for symptom relief were high in both treatment groups (87.5% mirabegron, 90.2% solifenacin) versus placebo (55.8%).
• Mirabegron showed a similar side effect profile to placebo, while solifenacin had a statistically significant increase in dry mouth and constipation.

Conclusions:

• Mirabegron and solifenacin offer comparable efficacy in managing pediatric OAB symptoms.
• Mirabegron appears to be a safer alternative due to a lower incidence of adverse events compared to solifenacin.